Merck Manual

Please confirm that you are a health care professional

honeypot link

Paget Disease of Bone

(Paget's Disease of Bone; Osteitis Deformans)

By

Julia F. Charles

, MD, PhD, Brigham and Women's Hospital

Reviewed/Revised May 2023
View Patient Education
Topic Resources

Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease may be asymptomatic or cause gradual onset of bone pain or deformity. Diagnosis is by x-ray. Treatment includes symptomatic measures and often medications, usually bisphosphonates.

Approximately 2 to 3% of adults > 55 years old in the United States have Paget disease, with a slight male predominance (1 General references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more General references ). Prevalence increases with age; however, overall prevalence seems to be decreasing. The disease is most common in the United Kingdom and European countries including Spain, France, and Italy, as well as in countries settled by European immigrants (eg,Australia, New Zealand, the United States, and Canada) (2 General references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more General references , 3 General references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more General references ). Paget disease is rare in Scandinavian countries and Asia.

General references

  • 1. Ralston SH, Corral-Gudino L, Cooper C, et al: Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. J Bone Miner Res 34(4):579-604, 2019. doi: 10.1002/jbmr.3657

  • 2. Reid IR: Recent advances in understanding and managing Paget's disease. F1000Res. 2019;8:F1000 Faculty Rev-1485. Published 2019 Aug 22. doi:10.12688/f1000research.19676.1

  • 3. Singer FR, Bone HG 3rd, Hosking DJ, et al: Paget's disease of bone: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99(12):4408-22, 2014. doi: 10.1210/jc.2014-2910

Etiology of Paget Disease of Bone

About 10% of patients with Paget disease have mutations of the SQSTM1 (sequestosome-1) gene, resulting in increased nuclear factor kappa-B activity, which increases osteoclast activity (1 Etiology references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Etiology references , 2 Etiology references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Etiology references ). Several other mutations associated with Paget disease have been identified, many affecting the RANK (receptor activator of nuclear factor kappa-B) signaling pathway that is critical for osteoclast generation and activity.

A viral etiology, such as measles, has been proposed because nuclear inclusions in diseased osteoclasts that are similar to those seen in paramyxovirus-infected cells have been seen on electron microscopy. Although a viral cause remains controversial, it is hypothesized that in genetically predisposed patients an as yet unidentified virus triggers abnormal osteoclast activity.

Etiology references

  • 1. Laurin N, Brown JP, Morissette J, Raymond V: Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588, 2002. doi: 10.1086/340731

  • 2. Rea SL, Walsh JP, Layfield R, et al: New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone. Endocr Rev 34(4):501-24, 2013. doi: 10.1210/er.2012-1034

Pathophysiology of Paget Disease of Bone

Any bone can be involved in Paget disease. The bones most commonly affected are the pelvis, femur, and skull. Other less commonly involved bones are the tibia, vertebrae, clavicle, and humerus.

Bone turnover is accelerated at involved sites. Pagetic lesions are metabolically active and highly vascular. Excessively active osteoclasts are often large and contain many nuclei. Osteoblastic repair is also hyperactive, causing coarsely woven, thickened lamellae and trabeculae. This abnormal structure weakens the bone, despite bone enlargement and areas of bone sclerosis.

Symptoms and Signs of Paget Disease of Bone

Paget disease of the bone is usually asymptomatic. If symptoms occur, they develop insidiously, with pain, stiffness, fatigue, and bone deformity. Bone pain is aching, deep, and occasionally severe, sometimes worse at night. Pain also may arise from compression neuropathy or osteoarthritis.

If the skull is involved, signs may include skull enlargement bitemporally and frontally (frontal bossing), dilated scalp veins, and nerve deafness in one or both ears. Symptoms may include vertigo, headaches, and hearing impairment. Deformities may develop from bowing of the long bones or osteoarthritis. Pathologic fractures may be the presenting manifestation. New onset or severe pain at a site of pagetic bone should prompt consideration of osteosarcoma.

Complications

The most common complication of Paget disease of bone is

Osteoarthritis occurs in up to 50% of patients and develops in joints adjacent to involved bone. Pathologic fracture is also common due to focal areas of weakened bone.

Diagnosis of Paget Disease of Bone

  • Plain x-rays

  • Elevated serum alkaline phosphatase or other markers of increased bone turnover

  • Bone scan to establish the extent and location of disease

Paget disease should be suspected in patients with the following:

  • Unexplained bone pain or deformity

  • Suggestive findings on x-ray

  • Unexplained elevation of serum alkaline phosphatase on laboratory tests done for other reasons, particularly if liver-sourced 5'-nucleotidase or gamma-glutamyl-transpeptidase (GGT) is normal

If Paget disease is suspected, plain x-rays and serum alkaline phosphatase, 25OH-vitamin D, creatinine, calcium, and phosphate levels should be obtained.

Characteristic laboratory findings include elevated serum alkaline phosphatase (increased anabolic activity of bone) but usually normal serum gamma-glutamyl-transpeptidase (GGT), 5'-nucleotidase, and serum phosphate levels. Serum calcium is usually normal, though in the setting of immobilization may be increased. If hypercalcemia is present, the patient should be evaluated for concurrent hyperparathyroidism. If alkaline phosphatase is not elevated or it is unclear whether the increased serum alkaline phosphatase is of bony origin (ie, if GGT is increased in proportion to alkaline phosphatase), a bone-specific alkaline phosphatase fraction can be measured. Serum markers of bone turnover, such as procollagen type I intact N-terminal propeptide (PINP) and C-telopeptide cross-links (CTX), may be elevated. A 25OH-vitamin D level and creatinine should be checked before treating symptomatic patients with bisphosphonates.

Confirmation on x-ray is required to establish the diagnosis. Characteristic x-ray findings include abnormal architecture with coarse trabeculae and cortical thickening and sclerosis. Involved bone may be enlarged, and pagetic lesions in the tibia or femur may result in bowing. Once a diagnosis of Paget's disease of bone is made on x-ray, a radionuclide bone scan using technetium-labeled phosphonates should be done to determine the extent of bone involvement. However, in cases of diagnostic uncertainty, a biopsy should be performed to exclude possible metastatic disease. A biopsy is also indicated for patients with known pagetic bone involvement who have worsening symptoms at the affected site to evaluate for osteosarcoma or other tumors (eg, giant cell tumor of bone).

Pearls & Pitfalls

  • Consider Paget disease of bone in older adults with elevated alkaline phosphatase but normal GGT levels.

Treatment of Paget Disease of Bone

  • Supportive care for symptoms and complications

  • Bisphosphonates if bone disease is symptomatic or active in bones at risk of complications

Supportive treatment of Paget disease of bone includes analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) for pain. Orthotics help correct abnormal gait caused by bowed lower extremities. Some patients require orthopedic surgery (eg, hip or knee replacement, decompression of the spinal cord). Weight bearing should be encouraged, and bed rest should be avoided.

Localized, asymptomatic disease may not require treatment.

Pharmacologic therapy

Pharmacologic therapy is indicated to treat pain clearly related to the pagetic process and not to another source (eg, osteoarthritis). In addition, some guidelines (1 Treatment references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Treatment references ), recommend treatment to

  • Prevent or retard progression of complications (eg, hearing loss, deformity, osteoarthritis, paraparesis or paraplegia related to vertebral Paget disease, or other neurologic deficits), particularly in a poor surgical candidate

  • Prevent or minimize bleeding if orthopedic surgery is planned at a site with pagetic involvement

  • Suppress excessive osteoclast activity when serum alkaline phosphatase (of bony origin) is > 2 times the normal level, even in the absence of symptoms

Although disease progression can be retarded by medications, existing deficits (eg, deformity, osteoarthritis, hearing loss, neural impingement) are not reversed.

Several antiresorptive agents that suppress osteoclast activity and decrease bone pain are available for treating Paget disease.

Bisphosphonates are the medication class of choice. The amino-bisphosphonates (bisphosphonates with an extra nitrogen atom) more effectively suppress markers of disease activity and provide more prolonged response. Among these, zoledronic acid is recommended as first-line therapy for Paget disease of bone in professional guidelines (1 Treatment references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Treatment references , 2 Treatment references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Treatment references ), whereas other amino-bisphosphonates (such as alendronate, risedronate, and pamidronate) are 2nd-line, and the simple bisphosphonates (bisphosphonates without an extra nitrogen atom, such as tiludronate and etidronate) are 3rd-line therapy. Zoledronic acid and pamidronate are administered intravenously, while all other bisphosphonates are oral medications. Hypocalcemia after zoledronic acid has been reported with serum 25OH-vitamin D levels ≤ 10ng/mL, and a level of > 25ng/ml is suggested to reduce the risk of hypocalcemia.

Synthetic salmon calcitonin is an alternative to bisphosphonates for patients intolerant of or resistant to them. Case reports suggest that denosumab may also be an alternative to bisphosphonates (3 Treatment references Paget disease of bone is a chronic disorder of the adult skeleton in which bone turnover is accelerated in localized areas. Normal matrix is replaced with softened and enlarged bone. The disease... read more Treatment references ); however, there are insufficient data to support its routine use.

Because bone turnover is increased, patients should ensure adequate intake of calcium and vitamin D, and supplements are often needed.

Treatment references

  • 1. Singer FR, Bone HG 3rd, Hosking DJ, et al: Paget's disease of bone: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99(12):4408-22, 2014. doi: 10.1210/jc.2014-2910

  • 2. Reid IR, Lyles K, Su G, et al: A single infusion of zoledronic acid produces sustained remissions in Paget disease: Data to 6.5 years. J Bone Miner Res 26(9):2261–2270, 2011. doi: 10.1002/jbmr.438

  • 3. Reid IR, Sharma S, Kalluru R, Eagleton C: Treatment of Paget's disease of bone with denosumab: Case report and literature review. Calcif Tissue Int 99(3):322–325, 2016. doi: 10.1007/s00223-016-0150-6

Key Points

  • Paget disease of bone is an often asymptomatic abnormality of bone metabolism, particularly among older adults.

  • Complications can include osteoarthritis, fractures, neural compression, osteosarcoma, and rarely hypercalcemia.

  • Confirmation is usually by x-rays showing findings such as bone sclerosis, coarse cortical trabeculation or cortical thickening, and bone bowing or enlargement.

  • First-line treatment is with bisphosphonates, preferably zoledronic acid.

Drugs Mentioned In This Article

Drug Name Select Trade
Calcidol, Calciferol, D3 Vitamin, DECARA, Deltalin, Dialyvite Vitamin D, Dialyvite Vitamin D3, Drisdol, D-Vita, Enfamil D-Vi-Sol, Ergo D, Fiber with Vitamin D3 Gummies Gluten-Free, Happy Sunshine Vitamin D3, MAXIMUM D3, PureMark Naturals Vitamin D, Replesta, Replesta Children's, Super Happy SUNSHINE Vitamin D3, Thera-D 2000, Thera-D 4000, Thera-D Rapid Repletion, THERA-D SPORT, UpSpring Baby Vitamin D, UpSpring Baby Vitamin D3, YumVs, YumVs Kids ZERO, YumVs ZERO
Reclast, Zometa, Zometa Powder
Binosto, Fosamax
Actonel, Atelvia
Aredia
Didronel
Fortical , Miacalcin
Prolia, XGEVA
View Patient Education
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz! 
iOS ANDROID
iOS ANDROID
iOS ANDROID
TOP